AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12932879 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal myomectomy
Number of subjects: 24
Study 12932879 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic myomectomy
Number of subjects: 24
Study 10993394 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9068393 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg alteplase
Number of subjects: 25
Study 1350141 — intervention group
Group type: EXPERIMENTAL
Intervention: TEWL measurements next to the wrist
Number of subjects: 14
Study 1350141 — intervention group
Group type: COMPARATOR
Intervention: Other volar forearm sites
Number of subjects: 14
Study 4009330 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration with solution A and solution B
Number of subjects: 100
Study 4009330 — intervention group
Group type: COMPARATOR
Intervention: Intravenous therapy
Number of subjects: 100
Study 29280064 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan in combination with background therapy (PDE‐5i)
Number of subjects: 0
Study 29280064 — intervention group
Group type: COMPARATOR
Intervention: Background therapy only (placebo arm)
Number of subjects: 0
Study 26194532 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist analogue administered at a dose interval of 3 days and/or a monthly dose of GnRHa during chemotherapy
Number of subjects: 38
Study 26194532 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist analogue
Number of subjects: 38
Study 26194532 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogues
Number of subjects: 38
Study 25450320 — intervention group
Group type: EXPERIMENTAL
Intervention: Protoconized anemia therapy with adjusted doses of erythropoietin, iron, and vitamin C based on Hb and ferritin levels.
Number of subjects: 266
Study 25450320 — intervention group
Group type: COMPARATOR
Intervention: Non‐intervention group with doses of erythropoietin and iron determined by the attending physician.
Number of subjects: 266
Study 25450320 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maintenance rate of target Hb levels.
Number of subjects: 266
Study 25450320 — intervention group
Group type: COMPARATOR
Intervention: Lower maintenance rate of target Hb levels.
Number of subjects: 266
Study 22435409 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil group (n = 24) using blended essential oils (lavender, clary sage, marjoram) in a 3% concentration cream, massaged daily on lower abdomen.
Number of subjects: 48
Study 22435409 — intervention group
Group type: COMPARATOR
Intervention: Synthetic fragrance group (n = 24) as control.
Number of subjects: 48
Study 20077275 — intervention group
Group type: EXPERIMENTAL
Intervention: Overtrained athletes
Number of subjects: 12
Study 20077275 — intervention group
Group type: COMPARATOR
Intervention: Control athletes
Number of subjects: 12
Study 18344428 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine, 5 mg orally every 8 hours for 1 week after 131I therapy
Number of subjects: 60
Study 18344428 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care with dexamethasone and dolasetron mesylate)
Number of subjects: 60
Study 16471104 — intervention group
Group type: EXPERIMENTAL
Intervention: 25G Quincke spinal needle
Number of subjects: 10
Study 16471104 — intervention group
Group type: COMPARATOR
Intervention: 27G Quincke spinal needle
Number of subjects: 10
Study 14560224 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate open surgical AAA repair
Number of subjects: 1136
Study 14560224 — intervention group
Group type: COMPARATOR
Intervention: Imaging surveillance every 6 months
Number of subjects: 1136
Study 10556111 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microgram twice daily)
Number of subjects: 50
Study 10556111 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone (100 microgram twice daily)
Number of subjects: 50
Study 10556111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8739023 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg Y-27152
Number of subjects: 27
Study 8739023 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg Y-27152
Number of subjects: 27
Study 8739023 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg Y-27152
Number of subjects: 27
Study 8739023 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg Y-27152 (fasting)
Number of subjects: 27
Study 8739023 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg Y-27152 (after food)
Number of subjects: 27
Study 8739023 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg Y-27152
Number of subjects: 27
Study 8739023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8739023 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg Y-27152 (multiple doses)
Number of subjects: 27
Study 8739023 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg Y-27152 (multiple doses)
Number of subjects: 27
Study 8739023 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg Y-27152 (multiple doses)
Number of subjects: 27
Study 2020506 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard advice plus recommendation to increase supplemental carrying by 50% (supplemental group)
Number of subjects: 66
Study 2020506 — intervention group
Group type: COMPARATOR
Intervention: Standard pediatric advice (standard group)
Number of subjects: 66
Study 6750476 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cephalothin
Number of subjects: 198
Study 6750476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 31477166 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT2Quit app (full version)
Number of subjects: 41
Study 31477166 — intervention group
Group type: COMPARATOR
Intervention: Control app (minimal version)
Number of subjects: 41
Study 29631362 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHAG + E2
Number of subjects: 30
Study 29631362 — intervention group
Group type: COMPARATOR
Intervention: GnRHAG + PL
Number of subjects: 30
Study 26746580 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude writing intervention (writing letters expressing gratitude)
Number of subjects: 0
Study 26746580 — intervention group
Group type: COMPARATOR
Intervention: Therapy-as-usual control group (no writing intervention)
Number of subjects: 0
Study 24852722 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at school age (first dose)
Number of subjects: 239934
Study 24852722 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG revaccination at school age
Number of subjects: 239934
Study 24852722 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal BCG vaccination
Number of subjects: 239934
Study 22865627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (30% heart rate reserve) for 25-40 min/session
Number of subjects: 56
Study 22865627 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity exercise (70% heart rate reserve) for 25-40 min/session
Number of subjects: 56
Study 22865627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (30% heart rate reserve) for 35-40 min/session
Number of subjects: 56
Study 22865627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (30% heart rate reserve) for 25 min/session
Number of subjects: 56
Study 22865627 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity exercise (70% heart rate reserve) for 25 min/session
Number of subjects: 56
Study 20609482 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI, escitalopram)
Number of subjects: 728
Study 20609482 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressant (TCA, nortriptyline)
Number of subjects: 728
Study 17921366 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal (300 kcal, 100% carbohydrate)
Number of subjects: 0
Study 17921366 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (30 g fat/m(2), 35% fat)
Number of subjects: 0
Study 17921366 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard test meal (478 kcal; 16.4% protein, 32.7% fat, 50.4% carbohydrate)
Number of subjects: 0
Study 16120118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole capsules (Zolax 50 mg once a day)
Number of subjects: 61
Study 16120118 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexetidine mouthrinses (Heksoral 0.1%, twice daily)
Number of subjects: 61
Study 16120118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole capsules and hexetidine mouthrinses for 14 days
Number of subjects: 61
Study 11934186 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment (debridement and short-term usage of antimicrobial agents)
Number of subjects: 90
Study 10386179 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPT
Number of subjects: 8
Study 10386179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8695556 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar injections of 5 ml of anaesthetic (study group 1)
Number of subjects: 56
Study 8695556 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar injections of local anaesthetic (study group 2)
Number of subjects: 56
Study 2062516 — intervention group
Group type: EXPERIMENTAL
Intervention: Early photocoagulation
Number of subjects: 0
Study 2062516 — intervention group
Group type: COMPARATOR
Intervention: Deferral of photocoagulation (control)
Number of subjects: 0
Study 2062516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescein leakage severity
Number of subjects: 0
Study 2062516 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary loss and dilatation
Number of subjects: 0
Study 2062516 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriolar abnormalities
Number of subjects: 0
Study 6132832 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (300 mg)
Number of subjects: 31
Study 6132832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 31145202 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogens (CEE) alone (0.625 mg/d)
Number of subjects: 27347
Study 31145202 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) with calcium and vitamin D supplementation (CaD)
Number of subjects: 27347
Study 31145202 — intervention group
Group type: COMPARATOR
Intervention: CEE + medroxyprogesterone acetate (MPA) (0.625 mg of CEE + 2.5 mg of MPA)
Number of subjects: 27347
Study 29203070 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting bioresorbable polymer stent (MiStent)
Number of subjects: 1398
Study 29203070 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting durable polymer stent (Xience)
Number of subjects: 1398
Study 27030534 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-AGE diet
Number of subjects: 20
Study 27030534 — intervention group
Group type: COMPARATOR
Intervention: High-AGE diet
Number of subjects: 20
Study 24655054 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA preterm infants
Number of subjects: 131
Study 24655054 — intervention group
Group type: COMPARATOR
Intervention: AGA preterm infants
Number of subjects: 131
Study 22835668 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation everolimus-eluting stents (EES)
Number of subjects: 625
Study 22835668 — intervention group
Group type: COMPARATOR
Intervention: First-generation sirolimus-eluting stents (SES)
Number of subjects: 625
Study 20642246 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 50 or 100 mg
Number of subjects: 849
Study 20642246 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone HCI IR 10 or 15 mg
Number of subjects: 849
Study 17643772 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 intradermal doses of 0.1 mL PCECV (Rabipur)
Number of subjects: 703
Study 17643772 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 simulated post‐exposure booster doses 1 year after primary vaccination
Number of subjects: 703
Study 17643772 — intervention group
Group type: EXPERIMENTAL
Intervention: PCECV (Rabipur)
Number of subjects: 703
Study 16224180 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy with biweekly administration of 1,000 mg/m² gemcitabine
Number of subjects: 19
Study 16224180 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 19
Study 15457754 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoliosis in-patient rehabilitation (SIR) program offering patient-specific physiotherapy including intensive therapist-assisted exercise for six weeks.
Number of subjects: 0
Study 15457754 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (control group).
Number of subjects: 0
Study 11157177 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual tracing of the perimeter
Number of subjects: 38
Study 11157177 — intervention group
Group type: EXPERIMENTAL
Intervention: Single largest diameter
Number of subjects: 38
Study 9526937 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration sevoflurane (8% in 2:1 N2O:O2 mixture)
Number of subjects: 40
Study 9526937 — intervention group
Group type: COMPARATOR
Intervention: Incremental sevoflurane (1% in 2:1 N2O:O2 mixture, increased by 1% every 2-3 breaths)
Number of subjects: 40
Study 7983291 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 422
Study 7983291 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 422
Study 2643772 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose subcutaneous heparin (12,500 units every 12 hours)
Number of subjects: 221
Study 2643772 — intervention group
Group type: COMPARATOR
Intervention: Low-dose subcutaneous heparin (5000 units every 12 hours)
Number of subjects: 221
Study 2643772 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose subcutaneous heparin
Number of subjects: 221
Study 2643772 — intervention group
Group type: COMPARATOR
Intervention: Low-dose subcutaneous heparin
Number of subjects: 221
Study 969073 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU)
Number of subjects: 0
Study 969073 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclophosphamide (Cytoxan)
Number of subjects: 0
Study 969073 — intervention group
Group type: COMPARATOR
Intervention: standard therapy
Number of subjects: 0
Study 7409300 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg o.d.)
Number of subjects: 0
Study 7409300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (200 mg t.i.d.)
Number of subjects: 0
Study 7409300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29962180 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin in combination with nimodipine
Number of subjects: 120
Study 29962180 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine (control group)
Number of subjects: 120
Study 29962180 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse reactions
Number of subjects: 120
Study 29687966 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation plus laser therapy and exercise (SM-LT-CE)
Number of subjects: 330
Study 29687966 — intervention group
Group type: COMPARATOR
Intervention: Laser therapy and exercise (LT-CE)
Number of subjects: 330
Study 29687966 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 330
Study 27412459 — intervention group
Group type: EXPERIMENTAL
Intervention: Social action volunteer befriending service plus usual care
Number of subjects: 0
Study 27412459 — intervention group
Group type: COMPARATOR
Intervention: Wait-list arm (control)
Number of subjects: 0
Study 24860893 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab + trastuzumab + docetaxel
Number of subjects: 808
Study 22824834 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mcg/h fentanyl patch
Number of subjects: 110
Study 22824834 — intervention group
Group type: COMPARATOR
Intervention: Placebo control patch
Number of subjects: 110
Study 21287795 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized continuous performance functions test (CPF test)
Number of subjects: 58
Study 21287795 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-ADHD children)
Number of subjects: 58
Study 17517060 — intervention group
Group type: EXPERIMENTAL
Intervention: Methodological and statistical features of RCTs in implant therapy
Number of subjects: 0
Study 17517060 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived clinical relevance
Number of subjects: 0
Study 17517060 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact on research
Number of subjects: 0
Study 17517060 — intervention group
Group type: EXPERIMENTAL
Intervention: Methodological and statistical quality of studies
Number of subjects: 0
Study 16163087 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel
Number of subjects: 50
Study 16163087 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 50
Study 11904104 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 288
Study 11904104 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel
Number of subjects: 288
Study 10527977 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant implants (NOR)
Number of subjects: 108
Study 10527977 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal rings (PVR)
Number of subjects: 108
Study 10527977 — intervention group
Group type: COMPARATOR
Intervention: Copper T 380A intrauterine devices (T-Cu)
Number of subjects: 108
Study 7588177 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (full dosage)
Number of subjects: 0
Study 7588177 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term antidepressants (in bipolar disorders)
Number of subjects: 0
Study 7588177 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term antidepressants (in dysthymias and personality disorders)
Number of subjects: 0
Study 7588177 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclics, MAOIs, and SSRIs
Number of subjects: 0
Study 7588177 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term antidepressant treatment
Number of subjects: 0
Study 2012292 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia with higher infusion rate
Number of subjects: 50
Study 2012292 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled epidural analgesia with lower infusion rate
Number of subjects: 50
Study 7044724 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral preoperative antibiotics and systemic peroperative antibiotics
Number of subjects: 90
Study 7044724 — intervention group
Group type: COMPARATOR
Intervention: Oral preoperative antibiotics
Number of subjects: 90
Study 7044724 — intervention group
Group type: COMPARATOR
Intervention: Systemic peroperative antibiotics
Number of subjects: 90
Study 31043346 — intervention group
Group type: EXPERIMENTAL
Intervention: PAAS technology
Number of subjects: 412
Study 31043346 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person facilitator-led PAAS small group
Number of subjects: 412
Study 31043346 — intervention group
Group type: COMPARATOR
Intervention: Literature control (home-mailed educational materials)
Number of subjects: 412
Study 29961920 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human EPO (rhEPO) administered acutely to healthy humans.
Number of subjects: 0
Study 29961920 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human EPO (rhEPO) administered acutely to mice.
Number of subjects: 0
Study 29961920 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic elevation of EPO in transgenic mice.
Number of subjects: 0
Study 29961920 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute injections of recombinant FGF23.
Number of subjects: 0
Study 27455318 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucerna (GL)
Number of subjects: 22
Study 27455318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra Glucose Control (UGC)
Number of subjects: 22
Study 27455318 — intervention group
Group type: COMPARATOR
Intervention: Oatmeal (OM)
Number of subjects: 22
Study 25154994 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic intramedullary nail
Number of subjects: 84
Study 25154994 — intervention group
Group type: COMPARATOR
Intervention: Conventional plating
Number of subjects: 84
Study 22209292 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV-6/11/16/18 vaccine
Number of subjects: 52
Study 22209292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 22209292 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent HPV-16 vaccine
Number of subjects: 52
Study 21119659 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about trial logic, voluntary nature, and rights to withdraw provided to patients.
Number of subjects: 1066
Study 21119659 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous trial experience
Number of subjects: 1066
Study 21119659 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 1066
Study 21119659 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <70 years
Number of subjects: 1066
Study 17201904 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patches with behavioural support
Number of subjects: 1050
Study 17201904 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal patches with behavioural support
Number of subjects: 1050
Study 16298890 — intervention group
Group type: EXPERIMENTAL
Intervention: Native language presentation
Number of subjects: 0
Study 16298890 — intervention group
Group type: COMPARATOR
Intervention: Secondary language presentation
Number of subjects: 0
Study 12887807 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 22
Study 12887807 — intervention group
Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 22
Study 10612536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine treatment (placebo-controlled)
Number of subjects: 363
Study 10612536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 7741639 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing with autologous adipose tissue
Number of subjects: 36
Study 2115379 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin, 1200 micrograms/day intranasally for 3 months
Number of subjects: 24
Study 2115379 — intervention group
Group type: COMPARATOR
Intervention: Immediate myomectomy
Number of subjects: 24
Study 94155 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophoretic mobility test (EM test)
Number of subjects: 130